{"filing":{"accession_number":"0001193125-26-349193","cik":"0001832038","ticker":"IVVD","company_name":"Invivyd, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ivvd-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-20260813.htm"},"events":[{"id":27595,"run_id":25161,"accession_number":"0001193125-26-349193","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Q2 2026 financial results for Invivyd, Inc., including PEMGARDA net product revenue of $14.3 million (21% growth YoY), R\u0026D expenses of $29.4 million, SG\u0026A expenses of $29.5 million, and a net loss of $44.4 million. The press release also highlights recent business developments including clinical trial progress on VYD2311. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.","company_name":"Invivyd, Inc.","ticker":"IVVD","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29185,"accession_number":"0001193125-26-349193","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Invivyd, Inc., including PEMGARDA net product revenue of $14.3 million (21% growth YoY), R\u0026D expenses of $29.4 million, SG\u0026A expenses of $29.5 million, and a net loss of $44.4 million. The press release also highlights recent business developments including clinical trial progress on VYD2311. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:27.617113+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29185,"accession_number":"0001193125-26-349193","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Invivyd, Inc., including PEMGARDA net product revenue of $14.3 million (21% growth YoY), R\u0026D expenses of $29.4 million, SG\u0026A expenses of $29.5 million, and a net loss of $44.4 million. The press release also highlights recent business developments including clinical trial progress on VYD2311. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:27.617113+00:00","company_name":"Invivyd, Inc.","ticker":"IVVD","filing_date":"2026-08-13"}]}